Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).

Umang Swami,Pedro Isaacsson Velho,Roberto H. Nussenzveig,Victor Sacristan Santos,Stephanie Erickson,Divya Dharmaraj,Ajjai Alva,Ulka N. Vaishampayan,John Esther,Andrew W. Hahn,Benjamin Louis Maughan,Emmanuel S. Antonarakis,Neeraj Agarwal

Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).

2020

Umang Swami
Pedro Isaacsson Velho
Roberto H. Nussenzveig
Victor Sacristan Santos
Stephanie Erickson
Divya Dharmaraj
Ajjai Alva
Ulka N. Vaishampayan
John Esther
Andrew W. Hahn
Benjamin Louis Maughan
Emmanuel S. Antonarakis
Neeraj Agarwal

329Background: Men with metastatic castration resistant prostate cancer harboring somatic mutant SPOP (mtSPOP) have improved progression free survival (PFS) on abiraterone than those with wild-type...

Keywords:

Systemic therapy
Mutation
Cancer research
Speckle-Type POZ Protein
Pathology
Somatic cell
Castration-sensitive prostate cancer
Medicine
SPOP
Progression-free survival
Prostate cancer
survival outcome
Mutant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations